Antibiotic with anti-cancer and apoptotic properties
Radiomimetic DNA-cleaving agent that produces double and single DNA strand breaks through an oxygen-radical-dependent mechanism
Highly cited
Bleomycin consists in a complex of 11 glycopeptide anti-cancer antibiotics originally isolated from Streptomyces verticillus. The dominant components of the complex are bleomycin A2 and B2, which typically represent >90% of the total weight. Bleomycin has found clinical application in the treatment of a range of tumors. Bleomycin acts by intercalation of DNA and RNA. In the presence of oxygen and metal ions (e.g. copper and iron), Bleomycin forms a pseudo-enzyme that induces DNA cleavage.
Product Details
Alternative Name:
Blenoxane
Formula:
C55H85N17O25S4
MW:
1512.6
Source:
Isolated from Streptomyces sp.
CAS:
9041-93-4
MI:
14: 1318
RTECS:
EC5991990
Purity:
≥98% (HPLC)
Appearance:
White crystalline solid.
Solubility:
Soluble in 100% methanol or water (20mg/ml).
Shipping:
Ambient
Long Term Storage:
-20°C
Use/Stability:
Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C.
Regulatory Status:
RUO - Research Use Only
Please mouse over
Product Literature References
A Proximity Ligation Method to Detect Proteins Bound to Single-Stranded DNA after DNA End Resection at DNA Double-Strand Breaks: F.C. Fowler & J.K. Tyler; Methods Protoc. 5, 3 (2022), Abstract;
Skin fibrosis and recovery is dependent on Wnt activation via DPP4: A. Jussila, et al.; J. Invest. Dermatol. 142, 1597 (2022), Abstract;
A model of the aged lung epithelium in idiopathic pulmonary fibrosis: H. Shaghaghi, et al.; Aging 13, 16922 (2021), Abstract; Full Text
Discovery of the S1P2 antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a preclinical candidate for the treatment of idiopathic pulmonary fibrosis: O. Mammoliti, et al.; J. Med. Chem. 64, 6037 (2021), Abstract;
Electrochemotherapy in 3D ocular melanoma spheroids using a customized electrode: M. Fiorentzis, et al.; J. Vis. Exp. 158, e60611 (2020), Abstract;
Inflammatory drivers of cardiovascular disease: molecular characterization of senescent coronary vascular smooth muscle cells: S. Stojanovic, et al.; Front. Physiol. 11, 520 (2020), Abstract; Full Text
Thymic stromal lymphopoietin protects in a model of airway damage and inflammation via regulation of caspase-1 activity and apoptosis inhibition: N. Shubin, et al.; Mucosal Immunol. 13, 584 (2020), Abstract; Full Text
Direct intrabronchial administration to improve the selective agent deposition within the mouse lung: S. Liao, et al.; J. Vis. Exp. 147, e59450 (2019), Abstract;
MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs: O. Keiji et al.; Oncotarget 9, 25844 (2018), Abstract; Full Text
ASF1a Promotes Non-homologous End Joining Repair by Facilitating Phosphorylation of MDC1 by ATM at Double-Strand Breaks.: K.Y Lee et al.; Mol. Cell 5, 51 (2017), Abstract; Full Text
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer: S. Duffy, et al.; PNAS 113, 9967 (2016), Application(s): Sensitivity to Genotoxic Agents, Yeast strains carrying each dCIN candidate
, Abstract; Full Text
Extracellular ATP mediates the late phase of neutrophil recruitment to the lung in murine models of acute lung injury: D. Shah, et al.; Am. J. Physiol. Lung Cell. Mol. Physiol. 306, L152 (2014), Abstract; Full Text
Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO: M. Kullberg, et al.; Mol. Pharm. 9, 2000 (2012), Abstract;
Bleomycin-induced alterations in DNA replication: relationship to DNA damage: J. Dziegielewski, et al.; Biochemistry 40, 704 (2001), Abstract;
Bleomycin: new perspectives on the mechanism of action: S.M. Hecht; J. Nat. Prod. 63, 158 (2000), Abstract;
Synergistic effects of laserthermia and bleomycinsulfate on micronuclei formation in cytokinesis-blocked HeLa cells: A.S. Monfared & H. Mozdarani; Irn. J. Med. Sci. 24, 87 (1999),
Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models: M. Schirner, et al.; Clin. Cancer Res. 4, 1331 (1998), Abstract;
Changes in c-Jun but not Bcl-2 family proteins in p53-dependent apoptosis of mouse cerebellar granule neurons induced by DNA damaging agent bleomycin: T. Araki, et al.; Brain Res. 794, 239 (1998), Abstract;
Induction of apoptosis by bleomycin in resting and cycling human lymphocytes: P. Vernole, et al.; Mutagenesis 13, 209 (1998), Abstract;
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs: M. Muller, et al.; J. Exp. Med. 188, 2033 (1998), Abstract;
Regulation of apoptosis in mouse hepatocytes and alteration of apoptosis by nongenotoxic carcinogens: J.G. Christensen, et al.; Cell Growth Differ. 9, 815 (1998), Abstract;
Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA: J.W. Sam, et al.; J. Biol. Chem. 273, 16090 (1998), Abstract;
Cleavage of tRNA by Fe(II)-bleomycin: A. Huttenhofer, et al.; J. Biol. Chem. 267, 24471 (1992), Abstract;
Chromatin structure during bleomycin-induced DNA damage and repair: B.P. Cuiffo, et al.; J. Free Radic. Biol. Med. 1, 139 (1985), Abstract;
Specificity of deoxyribonucleic acid cleavage by bleomycin, phleomycin, and tallysomycin: J. Kross, et al.; Biochemistry 21, 4310 (1982), Abstract;
Bleomycin and other antitumor antibiotics of high molecular weight: H. Umezawa; Antimicrob. Agents Chemother. (Bethesda) 5, 1079 (1965), Abstract;
Multiplex assay that distinguishes between healthy, early apoptotic, late apoptotic and necrotic cells, compatible with GFP and other fluorescent probes (blue or cyan)
Flow Cytometry, Fluorescence microscopy, Fluorescent detection | Print as PDF
